文献速递乳腺癌

PENELOPE-B试验最终生存结果:哌柏西利对比安慰剂用于新辅助化疗后高危HR+/HER2-乳腺癌伴残留病变患者

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.
PubMed 文献 · Ann Oncol · 2025-03-24

PENELOPE-B试验纳入1250例新辅助化疗后高危HR+/HER2-乳腺癌伴残留病变患者,随机接受哌柏西利或安慰剂联合内分泌治疗。中位随访77.8个月,6年OS率哌柏西利组82.4% vs 安慰剂组80.3%(HR 0.87,95%CI 0.67-1.14,P=0.31),iDFS等均无显著改善;探索性事后分析提示小叶癌亚组iDFS有获益趋势。

要点

  • 哌柏西利联合内分泌治疗未显著改善整体人群生存结局。
  • 6年OS率哌柏西利组82.4% vs 安慰剂组80.3%(HR 0.87,95%CI 0.67-1.14,P=0.31)。
  • 探索性事后分析提示小叶癌亚组iDFS有获益趋势(HR 0.52,95%CI 0.28-0.97,P=0.035)。

核心结论

  • 哌柏西利在整体人群中未显著改善生存结局。
  • 探索性事后分析提示接受哌柏西利的小叶癌患者iDFS有获益趋势。

研究设计与样本

  • PENELOPE-B试验为随机对照试验,纳入1250例经紫杉类新辅助化疗后具有残留病变和高复发风险的HR阳性/HER2阴性乳腺癌患者。
  • 患者随机接受哌柏西利125 mg或安慰剂,d1-21 q4w,共13个周期,同时联合内分泌治疗。

主要发现

  • 中位随访77.8个月,记录225例死亡(哌柏西利组108例,安慰剂组117例)。
  • 6年OS率哌柏西利组82.4% vs 安慰剂组80.3%(HR 0.87,95%CI 0.67-1.14,P=0.31)。
  • 哌柏西利对比安慰剂在iDFS、远处无病生存或局部区域复发率方面均无显著改善。
  • 分层分析显示各主要亚组均无获益。
  • 探索性事后分析显示小叶癌亚组中哌柏西利组OS有获益趋势(HR 0.45,95%CI 0.19-1.07,P=0.062),iDFS有获益趋势(HR 0.52,95%CI 0.28-0.97,P=0.035)。

局限性

  • 小叶癌亚组结果来自探索性事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The addition of 1 year of palbociclib to endocrine therapy (ET) did not improve invasive disease-free survival (iDFS) compared with placebo in the PENELOPE-B trial. In this article we report the final survival results of the PENELOPE-B trial. PATIENTS AND METHODS: The PENELOPE-B trial investigated whether adding 1 year of palbociclib to ET in hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer (BC) patients with residual disease and high relapse risk (clinical and pathological stage + estrogen receptor status and histological grade score ≥3 or 2 and ypN+) after taxane-based neoadjuvant chemotherapy would improve patient survival. Patients (n = 1250) were randomly assigned to receive either palbociclib 125 mg or placebo d1-21 q4w for 13 cycles in addition to ET. RESULTS: After a median follow-up of 77.8 months, we recorded 225 deaths (108 palbociclib; 117 placebo) with a 6-year overall survival (OS) rate of 82.4% in the palbociclib arm versus 80.3% in the placebo arm (hazard ratio 0.87, 95% confidence interval (CI) 0.67-1.14, P = 0.31). No significant improvement was noted for palbociclib versus placebo for iDFS, distant disease-free survival or locoregional relapse rate, even with longer follow-up. Upon stratified analysis, we found no benefits across major subgroups. However, exploratory post hoc analyses of the lobular BC (LBC) subgroup indicated a trend toward better survival outcomes in favor of palbociclib (hazard ratio 0.45, 95% CI 0.19-1.07, P = 0.062 for OS and hazard ratio 0.52, 95% CI 0.28-0.97, P = 0.035 for iDFS). CONCLUSION: The study concluded that palbociclib did not significantly improve survival outcomes in the overall population. Exploratory post hoc analyses suggested a trend toward better iDFS outcome in patients with LBC receiving palbociclib.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Loibl S, Martin M, Bonnefoi H, et al. Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy. Ann Oncol. 2025. PMID: 40139460. doi:10.1016/j.annonc.2025.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。